[ad_1]
John Cbadidy, chief investment officer at Arix Bioscience PLC (LON: ARIX), tells Proactive London its decision to invest $ 15 million (£ 11.3 million) in Imara – a company developing treatments for sickle cell disease
As a result of this transaction, Arix acquires a 10% interest in the company while expanding its portfolio.
Source link
